Список проголосовавших за комментарий " On The Wires<ul><li>Veracyte (<strong>VCYT</strong>) announced that Palmetto GBA, a Medicare Administrative Contractor, has finalized its coverage policy for the Percepta Bronchial Genomic Classifier. This local coverage determination makes Percepta the first genomic test to be covered by Medicare for improved lung cancer screening and diagnosis. Developed through the Medicare MolDx program, the policy will become effective March 13, 2017 and provides a framework for other participating MACs to follow.</li><li>Callidus Software (<strong>CALD</strong>) announced it has expanded its partnership with Salesforce. This new, multi-year deal enhances the position of CallidusCloud—a Salesforce Platinum ISV Partner delivering solutions on the AppExchange since 2006—by including new joint marketing investments, joint sales activities and technical alignment.</li><li>PPG (<strong>PPG</strong>) and Universal Display Corporation (<strong>OLED</strong>) announced that Universal Display will invest $15 million in PPG's Barberton, Ohio, manufacturing facility to double commercial production capacity for Universal Display's proprietary UniversalPHOLED phosphorescent emitter products. The expansion project, which will add more than 20 positions at the facility, is scheduled to be completed in the third quarter 2017.</li><li>Advaxis (<strong>ADXS</strong>) announced that the first patient has been enrolled and dosed in its AIM2CERV (Advaxis IMmunotherapy 2 prevent CERVical recurrence) trial, the only company-sponsored global phase 3 trial enrolling patients with advanced stage cervical cancer. The company plans to enroll ~450 patients at 150 global sites. </li><li>The Harrogate Bus Company, owned by Transdev Blazefield, buys eight electric buses from Volvo (<strong>VLVLY</strong>). The vehicles will operate in Harrogate, 90 km northeast of Manchester. The project was unveiled at an event on February 3 where Volvo's fully electric bus from Gothenburg was demonstrated.</li><li>Vale (<strong>VALE</strong>) disclosed in a regulatory filing that it expects to recognize impairments (with no cash effect) in its fertilizers segment, with an impact in its results of approximately $1.2 billion after tax, resulting from the agreement to sell certain assets for $2.5 billion announced in December 2016. Also, as a result of a lower price outlook for certain products, the co expects to recognize additional impairments (with no cash effect) in its base metals operations in Vale Newfoundland and Labrador (VNL) and Vale New Caledonia (VNC). The co has not yet finally determined the amount of these impairments in VNL and VNC, but based on current estimates the company expecte it to be significantly less than the impairment recognized on these assets in 2015.</li></ul>"